Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai Seeks US Approval for Livalo Generic, Submits ANDA
Sawai Pharmaceutical said on June 16 that the US FDA has accepted an application for the approval of the company’s Livalo (pitavastatin) generic drug, which was submitted by its US subsidiary. This is the first overseas regulatory filing for Sawai,…
To read the full story
Related Article
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Sawai Gets FDA Nod for Livalo Generic
February 13, 2017
- Sawai Files Myrbetriq Generic in US, Its 2nd Product after Livalo Copy
September 28, 2016
BUSINESS
- AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
June 18, 2026
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
- Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
June 17, 2026
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…